Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel

Bibliography

• VARADHACHARY GR, AJANI JA: Gastric cancer. Clin. Advances Hematol. Oncol. (2005) 3:118-124.
   PubMedGoogle Scholar
• VAN CUTSEM E: The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist (2004) 9(Suppl. 2):9-15.
   PubMed Web of Science ®Google Scholar
• CREW KD, NEUGUT AI: Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. (2004) 31:450-464.
   PubMed Web of Science ®Google Scholar
• BANG YJ, KANG WK, YOON-KOO K et al.: Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a Phase II trial. Jpn J. Clin. Oncol. (2002) 32:248-254.
   PubMed Web of Science ®Google Scholar
• SULKES A, SMYTH J, SESSA C et al.: Docetaxel (Taxotere) in advanced gastric cancer: results of a Phase II clinical trial: EORTC Early Clinical Trials Group. Br. J. Cancer (1994) 70:380-383.
   PubMed Web of Science ®Google Scholar
• EINZIG AI, NEUBERG D, REMICK SC et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol. (1996) 13:87-93.
   PubMed Web of Science ®Google Scholar
• HAWKINS R, CUNNINGHAM D, SOERBYE H et al.: Randomized Phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc. Am. Soc. Clin. Oncol. (2003) 22:257. Abstract 1032.
   Google Scholar
• AJANI J, FODOR M, TJULANDIN SA et al.: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. (2005) 23:5660-5667.
   PubMed Web of Science ®Google Scholar
• THUSS-PATIENCE P, KRETZSCHMAR A, REPP M: Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized Phase II study. J. Clin. Oncol. (2005) 23:494-501.
   PubMed Web of Science ®Google Scholar
• KETTNER E, RIDWELSKI K, KEILHOLZ U et al.: Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: results of two Phase II studies. Proc. Am. Soc. Clin. Oncol. (2001). Abstract 657.
   Google Scholar
• RIDWELSKI K, GEBAUER T, FAHLKE J et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. (2001) 12:47-51.
   PubMed Web of Science ®Google Scholar
• PARK SH, KANG WK, LEE HR et al.: Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5- fluorouracil-based regimen. Am. J. Clin. Oncol. (2004) 27:477-480.
   PubMed Web of Science ®Google Scholar
• ROTH AD, MAILBACH R, FALK S et al.: Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. (2004) 22:318s. Abstract 4020.
   Google Scholar
• MOISEYENKO V, AJANI J, TJULANDIN S et al.: Final results of a randomized controlled Phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-flouroruacil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J. Clin. Oncol. (2005) 23:308s. Abstract 4002.
   Google Scholar
• VANHOEFER U, ROUGIER P, WILKE H et al.: Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. (2000) 18:2648-2657.
   PubMed Web of Science ®Google Scholar
• OHTSU A, SHIMADA Y, SHIRAO K et al.: Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. (2003) 21:54-59.
   PubMed Web of Science ®Google Scholar
• ICLI F, CELIK I, AYKAN F et al.: A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluoruracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer (1998) 83:2475-2480.
   PubMed Web of Science ®Google Scholar
• WEBB A, CUNNINGHAM D, SCARFFE JH et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. (1997) 15:261-267.
   PubMed Web of Science ®Google Scholar
• ROSS P, NICOLSON M, CUNNINGHAM D: Prospective randomized trial of comparing mitomycin, cisplatin, and protracted venous infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. (2002) 20:1996-2004.
   PubMed Web of Science ®Google Scholar
• DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. J. Clin. Oncol. (2005) 23:308s. Abstract 4003.
   Google Scholar